JAMP Flecainide Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Flecainide acetate

Indications/Uses

AV nodal reciprocating tachycardia; arrhythmias associated w/ Wolff-Parkinson-White syndrome & similar conditions w/ accessory pathways. Paroxysmal atrial fibrillation in patients w/ disabling symptoms. Symptomatic sustained ventricular tachycardia. Premature ventricular contractions &/or non-sustained ventricular tachycardia which are causing disabling symptoms, where these are resistant to other therapy or when other treatment has not been tolerated. Maintenance of normal rhythms following conversion by other means.

Dosage/Direction for Use

Adult Supraventricular arrhythmia Initially 50 mg bd. If required, dose may be increased to max of 300 mg daily. Ventricular arrhythmia Initially 100 mg bd. Max daily dose: 400 mg. Progressively adjust dose to lowest level which maintains control of the arrhythmia after 3-5 days. Renal impairment (CrCl ≤35 mL/min/1.73 m²) Max initial dose: 100 mg daily or 50 mg bd.

Contraindications

Cardiac failure. Patients w/ history of MI who have either asymptomatic ventricular ectopics or nonsustained ventricular tachycardia; long standing atrial fibrillation in whom there has been no attempt to convert to sinus rhythm; haemodynamically significant valvular heart disease. Not to be given in patients w/ sinus node dysfunction, atrial conduction defects, 2nd degree or greater AV block, bundle branch or distal block.

MIMS Class

Cardiac Drugs

ATC Classification

C01BC04 - flecainide ; Belongs to class Ic antiarrhythmics.

Regulatory Classification

POM

Presentation/Packing

Form

JAMP Flecainide tab 100 mg

Packing/Price

1's

JAMP Flecainide

flecainide

Manufacturer:

Aizant Drug Research Solutions